Overview of clinical trials investigating targets within the adenosine signaling pathway in cancer

Molecular TargetClinicalTrials.gov IdentifierPharmaceutical SupplierAgentDesign Overview
Interventional Trials
A2aRNCT02655822CorvusCPI-444Phase 1/1bsingle agent and in combination with Atezolizumaballows prior PD-1/PD-L1advanced solid malignancies
NCT02403193Pablobio (Novartis)PBF-509Phase 1/1bsingle agent and in combination PDR001 (anti-PD1)allows prior PD-1/PD-L1non-small cell lung cancer
NCT03099161MerckMK-3814Phase 1single agent and in combination with Pembrolizumab(anti-PD-1);allows prior PD-1/PD-L1advanced solid malignancies
NCT02740985AstraZenecaAZD4635Phase 1single agent and in combination with Durvalumab (anti-PDL-1)allows prior PD-1/PD-L1advanced solid malignancies
CD73NCT02503774MedimmuneMEDI9447Phase 1combination with Durvalumab (anti-PDL-1) (no single agent)allows prior PD-1/PD-L1advanced solid malignancies
NCT03267589MedimmuneMEDI9447Phase 2single agent and in combination with Durvalumab (anti-PDL-1), Tremelilumab (anti-CTLA4), MEDI 0562 (anti-OX40)allows prior PD-1/PD-L1relapsed ovarian cancer
NCT02754141Bristol-Meyers-SquibbBMS-986179Phase 1/2asingle agent and in combination with Nivolumab (anti-PD-1)allows prior PD-1/PD-L1advanced solid malignancies
Noninterventional Trialsa
CD39/CD73NCT03255252Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy
NCT02567929Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patients With Breast Cancer

a“Noninterventional trials” refers to interventions targeting the adenosine-CD39-CD73-A2aR pathway, these trials may be otherwise interventional in terms of other treatment modalities, such as chemotherapy or radiation